Lyell Immunopharma, Inc. (LYEL)
| Market Cap | 522.79M +301.2% |
| Revenue (ttm) | 36,000 -41.0% |
| Net Income | -274.45M |
| EPS | -16.06 |
| Shares Out | 23.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,469 |
| Open | 23.24 |
| Previous Close | 23.60 |
| Day's Range | 22.25 - 23.67 |
| 52-Week Range | 7.65 - 45.00 |
| Beta | -0.07 |
| Analysts | Strong Buy |
| Price Target | 30.60 (+36.55%) |
| Earnings Date | May 12, 2026 |
About LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy random... [Read more]
Financial Performance
In 2025, Lyell Immunopharma's revenue was $36,000, a decrease of -40.98% compared to the previous year's $61,000. Losses were -$274.45 million, -19.98% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LYEL stock is "Strong Buy." The 12-month stock price target is $30.6, which is an increase of 36.55% from the latest price.
News
Lyell Immunopharma Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing next-generation CAR T-cell therapies, with ronde-cel showing high response rates and a favorable safety profile in pivotal trials. Manufacturing is fully in-house, and commercial launch is targeted for next year. LYL273 for solid tumors is also progressing, with promising early data and upcoming disclosures.
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma Transcript: The Citizens Life Sciences Conference 2026
Multiple pivotal trials are advancing for next-generation CAR T-cell therapies in lymphoma and colorectal cancer, with strong early efficacy and safety data. Major data updates are expected in H2, and financial resources are secured for continued development.
Lyell Immunopharma Transcript: Leerink Global Healthcare Conference 2026
Key updates include a new CFO hire, a $50M financing milestone, and strong clinical progress for the dual-targeted ronde-cel CAR T-cell therapy, which shows high response rates and a favorable safety profile. The company is also advancing a novel GCC CAR T-cell program for solid tumors, with promising early data and upcoming readouts.
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma Transcript: TD Cowen 46th Annual Health Care Conference
Significant clinical progress was highlighted for dual-targeting CAR T-cell therapies in lymphoma and colorectal cancer, with pivotal trials underway and promising early efficacy and safety data. Scalable manufacturing and a strong cash position support upcoming milestones through 2027.
Lyell Immunopharma Announces Participation in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)...
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)...
Lyell Immunopharma Transcript: Study Update
Ronde-cel demonstrated high response and durable remission rates in high-risk large B-cell lymphoma patients, with a favorable safety profile and strong translational data supporting its mechanism. LYL273 showed promising efficacy in metastatic colorectal cancer, with manageable safety and innovative design.
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)...
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety pro...
Lyell Immunopharma Transcript: Investor Update
Exclusive global rights to LYL273, a next-gen CAR T-cell therapy for metastatic colorectal cancer, were acquired, showing a 67% response rate in phase I U.S. trials and strong potential in a large, underserved market. Optimized safety protocols and robust manufacturing support rapid development.
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic color...
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for p...
Lyell Immunopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference
RondaCell, a dual-targeting CD19/20 CAR T therapy, is showing superior response and safety compared to current CD19 CARs, with pivotal trials in both third- and second-line lymphoma settings. Key data updates are expected by year-end, supporting its potential to disrupt the market.
Lyell Immunopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
RONDACELL, a dual-targeting CD19/CD20 CAR T therapy, is advancing through pivotal trials for large B-cell lymphoma, showing high response rates and a favorable safety profile. The company is leveraging in-house manufacturing, strong IP, and a robust financial position to pursue both hematologic and solid tumor indications, with a BLA filing targeted for 2027.
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatme...
Lyell Immunopharma Announces Participation in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generatio...
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with c...
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer...
Lyell Immunopharma Transcript: H.C. Wainwright “HCW@Home” Series
The conference highlighted strong clinical data for a dual-targeting CD19/20 CAR T-cell therapy, showing higher response and durability rates than current CD19 CARs, with a favorable safety profile and broad patient eligibility. Regulatory progress and a robust competitive position support a strategy targeting both third- and second-line lymphoma settings.
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer...
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer...
Lyell Immunopharma Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025
The team is advancing a dual-targeting CAR T-cell therapy for large B-cell lymphoma, now in pivotal trials with strong early efficacy and a clear FDA pathway. Manufacturing and commercial infrastructure are in place, and the pipeline includes next-gen solid tumor programs.